Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label randomized phase II study of the efficacy and safety of indisulam (E7070) in combination with capecitabine versus capecitabine monotherapy for the treatment of metastatic breast cancer patients following prior anthracycline and taxane therapy

Next Previous
X
Search
Trial Profile

An open-label randomized phase II study of the efficacy and safety of indisulam (E7070) in combination with capecitabine versus capecitabine monotherapy for the treatment of metastatic breast cancer patients following prior anthracycline and taxane therapy

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Indisulam (Primary) ; Capecitabine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Eisai Co Ltd

    • Most Recent Events

    • 30 Aug 2021 This trial has been completed in Spain (End Date: 21 Sep 2007), according to European Clinical Trials Database record.
    • 26 Jul 2020 This trial has been completed in United Kingdom according to European Clinical Trials Database record.
    • 06 Mar 2008 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top